Dallas, TX: ReportsandReports announce it will carry Drug Discovery Collaborations between Academia and the Pharmaceutical Industry: Cultural factors, intellectual property considerations, case studies, and future trends Market Research Report in its Store. Browse complete Drug Discovery Collaborations between Academia and the Pharmaceutical Industry: Cultural factors, intellectual property considerations, case studies, and future trends Report The pharmaceutical and biopharmaceutical industries are engaged in a business environment which is witnessing a dramatic escalation of R&D costs, key patent expiries, and sustained high attrition rates for new molecules in development. In response, pharmaceutical companies have recognized the need to expand the range of creative stimuli for their research processes in order to reinvigorate their drug discovery pipelines. Consequently the industry has sought to develop external collaborations not only with other companies but also more frequently with academia, to obtain access to new technologies to enhance their drug discovery capabilities and to in-license candidates for further development. Indeed, collaboration is becoming an essential component of today’s drug discovery efforts and it is commonly undertaken with multiple partners through an often iterative, continuous, and long lasting process, which adds to the complexity of efficiently managing both the collaboration itself and the data generated. This report explores the opportunities and challenges that are presented by collaboration with university researchers as well as identifying the key inputs from both the industrial and academic partners. The different organizational cultures and structures are examined along with consideration of the goals for each institution and the issues these create. The report discusses the various types of agreement which can be used, highlights legislation of importance to the appropriate protection of intellectual property, and presents case studies of notable collaborations In addition the report offers thoughts on the future for collaborative agreements and the benefits they will bring to both parties. Key features of the report Key benefits of the report Key highlights While academic institutions have attempted to remain true to the principles of open inquiry and intellectual freedom, political-economic forces such as globalization, an increasingly conservative political agenda, a tightening of public financial support for higher education and their changing role in society have resulted in the emergence of the corporate and entrepreneurial universities. The traditional view that there should be separation between the “ivory tower” academic based sciences and the more commercial and applied developmental research conducted in industry is now obsolete. Instead there is considerable synergy between basic research carried out in academia and applied research that is undertaken in the pharmaceutical industry. Major collaborations have a broad range of stakeholders, and failure to take all viewpoints into account can lead to significant opposition which ultimately may undermine the value of the partnership to both parties. Both the exact terms of the agreement and the presentation of those terms to the wider community are of crucial importance to a successful collaboration. Key questions answered by this report Table of Contents Drug Discovery Collaborations between Academia and the Pharmaceutical Industry: Cultural factors, intellectual property considerations, case studies, and future trends Executive summary 10 Background to collaborative research agreements 10 Critical issues for effective collaborations 11 Management of intellectual property rights 11 Case studies 12 The future of collaborations, licensing, and alliances 14 Chapter 1 Background to collaborative research agreements 16 Summary 16 Innovation and innovation models 17 The closed innovation model 17 The open innovation model 18 Consequences of the open innovation model 20 Intellectual property (IP) protection and open innovation 22 Types of collaborations 24 Sponsored research projects (SPR) contract research 24 Industry mentors for postdoctoral fellows 25 Gifts from companies for unrestricted research support 26 Research centers, industry affiliated programs, or consortia 26 Use of university laboratories, facilities, and centers by company researchers 27 Technological licensing and start-up venture creation 28 Advantages of collaborations between academia and industry 29 Advantages for academia 29 Advantages for the pharmaceutical industry 30 Disadvantages of collaborations between academia and industry 31 Disadvantages for academia 31 Practical difficulties in negotiating and managing a collaboration 31 Deleterious effects on faculty and students 32 Affect on the university reputation and financial challenges 32 Disadvantages for the pharmaceutical industry 33 Commercial interests are a low priority amongst academics 33 Discord regarding intellectual property rights 33 Types of collaboration agreements 34 One-to-one research collaborative agreements 36 Model consortium agreements 37 Identification of suitable collaborators and research partners 38 Strategic fit 39 Impact on internal strengths and weaknesses 39 Impact on strategic direction 40 Critical factors for successful collaboration resource planning 40 Clear support from senior management 40 Dedicated project management for each collaboration team 41 Complimentary strategy for both entities involved in the collaboration 41 Commitment to time and financial resources 41 Commitment to a supportive environment that fosters innovation 41 Assimilation of new knowledge by the sponsoring pharmaceutical company 42 Formulation of a well-defined collaboration agreement 42 Understanding the drafting of contractual terms and conditions 42 Definitions of the agreement 42 Collaboration agreement outline 43 Negotiating the terms and conditions of an agreement 48 Academic institution considerations 48 Pharmaceutical and biopharmaceutical industry considerations 48 License agreements 48 Upfront payments or signing fees 51 Annual or other periodic fees 51 Milestone payments 52 Duration and termination 53 Chapter 2 Critical issues for effective collaborations 56 Summary 56 Introduction 57 Cultural, change management, and goal alignment challenges 57 Organizational culture 57 The culture of academia 59 Pharmaceutical industry corporate culture 60 Corporate management and research collaborations 62 Management of open innovation and open science disclosure procedures 64 Lack of transparency between collaborating partners 65 Mismatch in time scales between academic study and commercial drive for results 65 Managing conflict and bridging cultural gaps between collaborating partners 65 Difference in research questions addressed by academia and industry 66 Effectiveness and efficiency of knowledge management and knowledge transfer 66 Institutional incentives and integration of research and educational missions 66 University reward and incentive structures 66 Potential misuse of student time and conflicts of interest 67 Payment of indirect costs incurred by the university 68 Goal alignment challenges in research collaborations 69 Challenges associated with technology and knowledge transfer 70 Challenges associated with the knowledge transfer process 70 Challenges associated with the technology transfer process 73 Chapter 3 Management of intellectual property rights 78 Summary 78 Introduction 79 Intellectual property rights and national policy considerations 80 WTO Trade-Related Aspects of Intellectual Property Rights (TRIPS) 80 The Bayh-Dole Act in the US 82 The Cooperative Research and Technology Enhancement (CREATE) Act 83 European position on patents and intellectual property protection 84 Intellectual property protection issues in Brazil 85 Russian legislation to strengthen regulation of pharmaceutical IP 86 Latest regulatory and legislative changes in India 87 Patent laws and WTO TRIPS in China 88 R&D collaborations and the uncertainty of intellectual property rights 91 The duration of patent examinations 91 Economic and strategic uncertainty for the industry 94 Uncertainties over publication of proprietary knowledge by academics 96 Uncertainties over disclosure of unprotected information 96 Conducting R&D in countries with weak IPR protection 97 Negotiating and bargaining associated with IPR 98 Protection of trade secrets 98 Protection of patentable IP 101 Chapter 4 Case studies 106 Summary 106 AstraZeneca and the University of Virginia 107 Review of the collaboration by AstraZeneca 109 Management of IP and entrepreneurial activities at UVa 109 AstraZeneca optimizes collaboration through interoperable technologies 110 Roche and the Translational Medicine Research Hub in Singapore 110 Management of IP and entrepreneurial activities at A*STAR 112 Industry collaboration with the University of Dundee and the Medical Research Council (MRC) 113 Management of IP and entrepreneurial activities at DSTT 114 Partnership of Sanofi-Aventis with the French Life Sciences and Healthcare Alliance (AVIESAN) 115 Collaborative alliance between GlaxoSmithKline and the Harvard Stem Cell Institute (HSCI) 115 Other GSK collaborations 116 Problematic collaborations 118 The Scripps Research Institute and Novartis 118 The Scripps Research Institute (TSRI) 118 Novartis AG 119 Collaboration Agreement between TSRI and Novartis 119 The Scripps Research Institute and Pfizer 121 The University of California Berkeley (UCB) and Novartis Agricultural Discovery Institute, Inc (NADII) 121 Controversial aspects 122 Conclusion 124 Chapter 5 The future of collaborations, licensing, and alliances 128 Summary 128 Introduction 129 Changing paradigms in traditional universities 130 The evolution of the corporate university 130 The emergence and evolution of the entrepreneurial university 132 Synergy between ivory tower academics and entrepreneurial scientists 135 The emergence and growth of research clusters and incubator hubs 138 Institutional changes to European university practices 140 Science parks 142 Incubator or enterprise hub models 144 Virtual incubators 145 The Triple Helix model of university–industry–government 147 Appendix 149 Methodology statement 149 Primary data and information gathering 149 Secondary data and information gathering 150 Glossary of abbreviations and acronyms 151 Index 160 Browse complete Drug Discovery Collaborations between Academia and the Pharmaceutical Industry: Cultural factors, intellectual property considerations, case studies, and future trends Report Browse all Healthcare Market Research Reports Browse all Business Insights Market Research Reports Browse all Latest Report Related Reports: Biomarkers in Drug Discovery – Optimizing Drug Discovery Timeline and Costs The Future of Biobanks: Regulation, ethics, investment and the humanization of drug discovery About Us: Contact:
Reports and Reports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004
Website: http://www.reportsandreports.com/
Blog: http://reportsnreports.wordpress.com/
Blog: http://reportsandreports.blogspot.com/
Drug Discovery Collaborations between Academia and the Pharmaceutical Industry of Business Insights now available at ReportsandReports
Posted by
Unknown
on